Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai And Daiichi Sankyo To Strengthen In-house R&D Capabilities

This article was originally published in PharmAsia News

Executive Summary

To strengthen research and development capability, Eisai will establish quasi-venture enterprise units inside the company. The units will conduct new drug discovery and product commercialization. The move is aimed to reorganize the company's domestic and overseas research staff in oncology and other areas and speed up new drug development. Along the same lines, Daiichi Sankyo will utilize Ranbaxy's research facilities and expand its R&D capabilities. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel